Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview

Over the past years, the identification of genetic alterations in oncogenic drivers in non-small cell lung cancer (NSCLC) has significantly and favorably transformed the outcome of patients who can benefit from targeted therapies such as tyrosine kinase inhibitors. Among these genetic alterations, a...

Full description

Bibliographic Details
Main Authors: Delphine Antoni, Hélène Burckel, Georges Noel
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
ALK
Online Access:https://www.mdpi.com/2072-6694/13/10/2394